Pharma Equity Group A/S

Equities

PEG A

DK0061155009

Investment Holding Companies

Market Closed - Nasdaq Copenhagen 10:08:32 2024-05-01 am EDT 5-day change 1st Jan Change
0.24 DKK -2.04% Intraday chart for Pharma Equity Group A/S -8.40% -44.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051 CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024 CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial CI
Pharma Equity Group A/S Approves Board Appointments CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method MT
Pharma Equity Group A/S Announces Board Changes CI
Reponex Pharmaceuticals A/S Announces CEO Changes CI
Reponex Pharmaceuticals A/S Names Dr Christopher M Burton MD, PhD as Chief Medical Officer CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Reponex Pharmaceuticals A/S completed the acquisition of Pharma Equity Group A/S. CI
Blue Vision A/S will Change its Name to Pharma Equity Group A/S CI
Blue Vision A/S Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Blue Vision A/S (CPSE:BLVIS A) made an offer to acquire Reponex Pharmaceuticals A/S. CI
Chart Pharma Equity Group A/S
More charts
Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. PEG A Stock
  4. News Pharma Equity Group A/S
  5. Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method